Why is this ASX 300 stock rocketing 17% today?

Let's see what is getting investors excited today.

Clarity Pharmaceuticals Ltd (ASX: CU6) shares are having a strong session on Monday.

In early trade, the ASX 300 stock jumped as much as 17% to $4.26 before pulling back.

At the time of writing, the clinical-stage radiopharmaceutical company's shares are still up around 5%.

Ecstatic woman looking at her phone outside with her fist pumped.

Image source: Getty Images

Why is this ASX 300 stock jumping?

Investors appear to be responding positively to an update from the company regarding new trial data for its prostate cancer imaging technology.

The company revealed that results from the Co-PSMA study were presented at the European Association of Urology (EAU) Annual Congress 2026 in London. The data has also been accepted for publication in the European Urology journal.

The trial evaluated Clarity's diagnostic product, 64Cu-SAR-bisPSMA, in patients experiencing biochemical recurrence of prostate cancer after surgery.

Importantly, the study compared the ASX 300 stock's imaging technology with a current standard-of-care PSMA PET scan.

The results showed that Clarity's agent detected significantly more cancer lesions than the standard scan. Across the study participants, the new imaging approach identified 63 lesions compared with 24 detected using the standard-of-care method.

In addition, 78% of patients had a positive scan using 64Cu-SAR-bisPSMA compared with 36% using the existing imaging agent, highlighting a potential improvement in detecting recurrent prostate cancer.

The study also showed a higher true positive rate and lower false negative rate for the company's imaging technology.

Why this matters

Detecting prostate cancer recurrence earlier and more accurately can significantly influence treatment decisions.

According to the trial data, the improved imaging results led to changes in planned patient management in 44% of participants, with many switching from surveillance to targeted radiotherapy.

These findings add to the growing body of evidence supporting the SAR-bisPSMA platform, which is designed as a targeted copper theranostic. This technology has the potential to be used both for cancer imaging and treatment depending on the isotope used.

Looking ahead, the company intends to combine results from this study with data from other trials, including the Phase II COBRA study and the Phase III AMPLIFY trial.

Together, these results are expected to support a future regulatory submission to the US Food and Drug Administration (FDA) for approval of 64Cu-SAR-bisPSMA in patients with recurrent prostate cancer.

The ASX 300 stock's executive chair, Dr Alan Taylor, commented:

The extraordinary quality of the academic research is coupled with the feverish pace of commercialisation where our registrational Phase III trials, AMPLIFY and CLARIFY, are nearing completion. We have recently shared that AMPLIFY reached its target number of participants with rising or detectable PSA after initial definitive treatment at clinical sites across the US and Australia in just 9 months since imaging the first patient, and we look forward to collecting and analysing the final study data.

Combined with results from the Co-PSMA and COBRA trials, we believe it will constitute a compelling application for approval of 64Cu-SAR-bisPSMA by regulatory authorities for the BCR indication.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »